HomeCompareVEMLY vs ABBV

VEMLY vs ABBV: Dividend Comparison 2026

VEMLY yields 3.16% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VEMLY wins by $532.53M in total portfolio value· pulled ahead in Year 3
10 years
VEMLY
VEMLY
● Live price
3.16%
Share price
$61.10
Annual div
$1.93
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$532.64M
Annual income
$502,067,393.30
Full VEMLY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VEMLY vs ABBV

📍 VEMLY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVEMLYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VEMLY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VEMLY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VEMLY
Annual income on $10K today (after 15% tax)
$268.19/yr
After 10yr DRIP, annual income (after tax)
$426,757,284.31/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VEMLY beats the other by $426,736,228.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VEMLY + ABBV for your $10,000?

VEMLY: 50%ABBV: 50%
100% ABBV50/50100% VEMLY
Portfolio after 10yr
$266.37M
Annual income
$251,046,082.53/yr
Blended yield
94.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VEMLY
No analyst data
Altman Z
92.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VEMLY buys
0
ABBV buys
0
No recent congressional trades found for VEMLY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVEMLYABBV
Forward yield3.16%3.06%
Annual dividend / share$1.93$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$532.64M$102.3K
Annual income after 10y$502,067,393.30$24,771.77
Total dividends collected$530.39M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VEMLY vs ABBV ($10,000, DRIP)

YearVEMLY PortfolioVEMLY Income/yrABBV PortfolioABBV Income/yrGap
1$11,331$631.04$11,550$430.00$219.00ABBV
2$13,461$1,336.51$13,472$627.96$11.00ABBV
3← crossover$17,371$2,967.67$15,906$926.08+$1.5KVEMLY
4$25,745$7,158.30$19,071$1,382.55+$6.7KVEMLY
5$47,377$19,830.38$23,302$2,095.81+$24.1KVEMLY
6$118,905$68,211.50$29,150$3,237.93+$89.8KVEMLY
7$447,217$319,988.13$37,536$5,121.41+$409.7KVEMLY
8$2,728,079$2,249,556.59$50,079$8,338.38+$2.68MVEMLY
9$28,568,720$25,649,676.29$69,753$14,065.80+$28.50MVEMLY
10$532,635,924$502,067,393.30$102,337$24,771.77+$532.53MVEMLY

VEMLY vs ABBV: Complete Analysis 2026

VEMLYStock

Venture Corporation Limited provides technology solutions, products, and services in Singapore, the Asia Pacific, and internationally. The company operates through Advanced Manufacturing & Design Solutions, and Technology Products & Design Solutions segments. It engages in the design, manufacture, assemble, installation, and distribution of electronic, and other computer products and peripherals; manufacture and sale of terminal units; development and marketing of color imaging products for label printing; and research and development of biotechnology, life, and medical science products, as well as engages in repair of engineering and scientific instruments. The company is also involved in the provision of engineering, customization, logistics, and repair services; information system development and support services; design solutions and services; administrative and technical, and management services; and manufacturing, product design and development, engineering, and supply-chain management services. In addition, it engages in the manufacturing, fabricating, and dealing of precision plastic tools, components and sub-assemblies; design, customization, and marketing of tool-making and precision engineering solutions; manufacture of plastic injection molds and moldings with secondary processes and subassembly; manufacture of high technology products; and import and export of electronic parts, components, equipment, devices, and instruments. Further, the company wholesales computer hardware and peripheral equipment; manufactures and repairs engineering and scientific instruments; and manufactures and sells data and telecommunications products in industrial electronics industries. Additionally, the company manages portfolio of approximately 5,000 products and solutions. Venture Corporation Limited was incorporated in 1984 and is headquartered in Singapore.

Full VEMLY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VEMLY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VEMLY vs SCHDVEMLY vs JEPIVEMLY vs OVEMLY vs KOVEMLY vs MAINVEMLY vs JNJVEMLY vs MRKVEMLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.